UNLABELLED: Binding of advanced glycation end products (AGEs) to their receptor (RAGE) increases oxidative stress and inflammation and may be involved in liver injury and subsequent carcinogenesis. Soluble RAGE (sRAGE) may neutralize the effects mediated by the AGE/RAGE complex. Epidemiologic studies examining sRAGE or AGEs in association with liver cancer are lacking. We examined the associations between prediagnostic serum concentrations of sRAGE or Nϵ-(carboxymethyl)-lysine (CML)-AGE and hepatocellular carcinoma in a case-cohort study within a cohort of 29,133 Finnish male smokers who completed questionnaires and provided a fasting blood sample between 1985 and 1988. During follow-up beginning 5 years after enrollment through April 2006, 145 liver cancers occurred. Serum concentrations of sRAGE, CML-AGE, glucose, and insulin were measured in case subjects and 485 randomly sampled cohort participants. Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) were available in most cases and in a subset of the study population. Weighted Cox proportional hazards regression was used to calculate relative risks (RR) and 95% confidence intervals (CI) adjusted for age, years of smoking, and body mass index. sRAGE and CML-AGE concentrations were inversely associated with liver cancer. Further adjustment for glucose and insulin or exclusion of case subjects with chronic HBV or HCV did not change the associations. CONCLUSION: Our results support the hypothesis that sRAGE is inversely associated with liver cancer. The findings need confirmation, particularly in populations that include women and nonsmokers. (HEPATOLOGY 2013 ).
UNLABELLED: Binding of advanced glycation end products (AGEs) to their receptor (RAGE) increases oxidative stress and inflammation and may be involved in liver injury and subsequent carcinogenesis. Soluble RAGE (sRAGE) may neutralize the effects mediated by the AGE/RAGE complex. Epidemiologic studies examining sRAGE or AGEs in association with liver cancer are lacking. We examined the associations between prediagnostic serum concentrations of sRAGE or Nϵ-(carboxymethyl)-lysine (CML)-AGE and hepatocellular carcinoma in a case-cohort study within a cohort of 29,133 Finnish male smokers who completed questionnaires and provided a fasting blood sample between 1985 and 1988. During follow-up beginning 5 years after enrollment through April 2006, 145 liver cancers occurred. Serum concentrations of sRAGE, CML-AGE, glucose, and insulin were measured in case subjects and 485 randomly sampled cohort participants. Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) were available in most cases and in a subset of the study population. Weighted Cox proportional hazards regression was used to calculate relative risks (RR) and 95% confidence intervals (CI) adjusted for age, years of smoking, and body mass index. sRAGE and CML-AGE concentrations were inversely associated with liver cancer. Further adjustment for glucose and insulin or exclusion of case subjects with chronic HBV or HCV did not change the associations. CONCLUSION: Our results support the hypothesis that sRAGE is inversely associated with liver cancer. The findings need confirmation, particularly in populations that include women and nonsmokers. (HEPATOLOGY 2013 ).
Authors: Eray Yagmur; Frank Tacke; Claudia Weiss; Birgit Lahme; Michael P Manns; Paul Kiefer; Christian Trautwein; Axel M Gressner Journal: Clin Biochem Date: 2006-01 Impact factor: 3.281
Authors: Shan Zeng; Nikki Feirt; Michael Goldstein; James Guarrera; Nikalesh Ippagunta; Udeme Ekong; Hao Dun; Yan Lu; Wu Qu; Ann Marie Schmidt; Jean C Emond Journal: Hepatology Date: 2004-02 Impact factor: 17.425
Authors: Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze Journal: J Transl Med Date: 2009-03-17 Impact factor: 5.531
Authors: Guellue Cataldegirmen; Shan Zeng; Nikki Feirt; Nikalesh Ippagunta; Hao Dun; Wu Qu; Yan Lu; Ling Ling Rong; Marion A Hofmann; Thomas Kislinger; Sophia I Pachydaki; Daniel G Jenkins; Alan Weinberg; Jay Lefkowitch; Xavier Rogiers; Shi Fang Yan; Ann Marie Schmidt; Jean C Emond Journal: J Exp Med Date: 2005-02-07 Impact factor: 14.307
Authors: Wen-Qing Li; Yikyung Park; Katherine A McGlynn; Albert R Hollenbeck; Philip R Taylor; Alisa M Goldstein; Neal D Freedman Journal: Hepatology Date: 2014-05-20 Impact factor: 17.425
Authors: Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254